In a significant move strengthening its technological capabilities, AstraZeneca has appointed Arm Holdings Chief Executive Rene Haas to its board as a non-executive director, effective from next month. The appointment comes as Britain’s most valuable public company seeks to enhance its expertise in artificial intelligence and data science.
The Cambridge-based pharmaceutical giant has also secured Birgit Conix, chief financial officer of Swiss hearing care specialist Sonova, who will join the board in February. These strategic appointments are part of a broader board refresh, as four current non-executive directors approach their nine-year tenure limits.
Michel Demaré, AstraZeneca’s chairman, praised Haas’s extensive experience in microprocessors, semiconductors, and software engineering, highlighting the increasing importance of technology in modern drug discovery. The appointment particularly emphasises AstraZeneca’s commitment to leveraging artificial intelligence and advanced data analytics in its pharmaceutical research.
Haas, who orchestrated Arm’s successful New York flotation last year, brings valuable expertise from leading one of Cambridge’s most prominent technology companies. His appointment comes at a crucial time when AstraZeneca faces challenges in the Chinese market, where authorities are investigating employee activities.
The pharmaceutical company, which has seen remarkable growth under Chief Executive Sir Pascal Soriot since 2012, continues to strengthen its position in oncology treatments. AstraZeneca’s shares closed at £105.24 in London, marking a modest 0.5 per cent increase, though remaining down 2 per cent for the year.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.